SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce cardiovascular mortality in type 2 diabetes independent of glycemic control. The primary mechanism responsible for their cardiorenal protection is:

• A Reduction of HbA1c by 1-1.5%, decreasing glycemic burden on heart and kidneys
• B Natriuresis and osmotic diuresis reducing preload, and reduction in interstitial fibrosis via NLRP3 inflammasome inhibition ✓
• C Augmentation of GLP-1 secretion, which has direct cardioprotective effects
• D Upregulation of AMPK in cardiac tissue, improving energy substrate utilization

Explanation

SGLT2 inhibitors block glucose and sodium cotransport in the proximal tubule, causing glycosuria, natriuresis, and osmotic diuresis. The cardiorenal benefits (shown in EMPA-REG OUTCOME and DAPA-HF trials) are largely independent of glucose-lowering and occur too quickly for glycemic mechanisms. Key mechanisms include: (1) reduced plasma volume and preload via natriuresis/diuresis; (2) decreased afferent arteriolar pressure through tubuloglomerular feedback activation; (3) reduction in cardiac and renal fibrosis partly via inhibition of NLRP3 inflammasome; and (4) a shift in cardiac metabolism toward fatty acid oxidation (producing more ketones as energy substrate). These drugs are now recommended in HFrEF patients irrespective of diabetes status.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.